Cipla launches ‘CIPtest’ rapid antigen detection test for COVID-19 diagnosis

Validated and approved by ICMR, the test is found to have specificity and sensitivity of 98.09% and up to 75% respectively. This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit

0
62
Mumbai: Cipla Limited has announced its partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.
This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.
The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient’s body, generating results within 15-20 minutes. Only authorized labs are permitted by ICMR to conduct rapid antigen testing. The test will be marketed under the brand name ‘CIPtest’.
Validated and approved by ICMR, the test is found to have specificity and sensitivity of 98.09% and up to 75% respectively. The test is not only rapid with a quick turn-around time but also enables easy interpretation of results without the need of any additional instrument. Cipla’s expansive distribution network will help in ensuring the supply of kits across the country.